For most Americans, thalidomide is remembered as a drug that never made it to American shelves — a European tragedy, halted in its tracks by a single federal scientist. That version of the story, survivors say, is incomplete. The drug did reach U.S. patients, thousands of them, and the children of the women who took it are now middle-aged adults seeking something they say they have never been given: official recognition that they exist.
The episode begins in late 1960, when the Cincinnati-based pharmaceutical company William S. Merrell applied to the Food and Drug Administration for approval of a German-made sedative. The company had every reason to expect a routine review. The application, in the company's accounting, was expected to sail through the process and put the product on store shelves in time for Christmas.
It did not. The drug was not approved that year, and it was not approved the following year either. What interrupted the process was a persistent medical reviewer at the FDA who dug into the drug's safety record and refused to let it through for general use. Her name was Dr. Frances Oldham Kelsey, and her opposition to the application fundamentally altered how the agency evaluates and clears new medicines.
Kelsey is the figure most closely associated with preventing thalidomide's approval in the United States. An Associated Press photograph from Oct. 15, 1962, shows her in Washington holding three packages of Contergan, the German brand name for thalidomide — a reminder that the drug was already an established, marketed product elsewhere even as it was being blocked here. Her stand is widely credited with changing the FDA's testing and approval process, producing the more demanding regulatory machinery that governs drug approval today.
The political reward for that work was immediate. President John F. Kennedy publicly praised Kelsey for sparing the United States "this terrible human tragedy which has been visited on families in Germany," a line that helped cement her place in regulatory history. But the reassurance embedded in that praise — that America had been spared — is precisely the claim survivors are now challenging.
Here is the part of the story that the familiar telling leaves out. Even with approval blocked, doctors were already giving thalidomide to thousands of patients in the United States, including pregnant women. Some of the women who took it gave birth to children with severely deformed limbs. Those children are adults now, and they are asking the federal government to formally acknowledge their existence — a request that, they say, is complicated by the fact that many Americans, including some physicians, still believe what happened overseas simply did not happen on American soil.
Gwen Riechmann was born with phocomelia, the shortened limb deformity that is the signature birth defect associated with thalidomide. She described the gap between official history and personal experience in blunt terms: "We go to doctors today who say it didn't happen here in the United States. Oh yeah, it did." The disbelief, in her telling, is not hypothetical — it is something survivors encounter repeatedly, inside exam rooms, decades after the fact.
That makes the survivors' push for recognition more than a symbolic gesture. If a physician does not believe thalidomide exposure occurred in the United States, the exposure is less likely to be considered in a differential diagnosis, less likely to be documented in a medical record, and less likely to be understood by a new doctor treating the same patient years later. A count the government does not acknowledge is, in effect, a population that health care can lose track of.
Phocomelia itself is rare, but it is somewhat more common outside the United States, in countries such as Britain and Germany, where thalidomide was more widely sold. That imbalance is part of why American survivors can end up statistically invisible: the condition and the exposure are associated with places where the drug was approved, and less strongly with the United States, where it was not.
Riechmann's own history runs straight through that blind spot. When her mother was pregnant with her in the early 1960s, a doctor gave the expectant mother a new sedative. It was, in Riechmann's account, a routine act of medical care — a prescription written for a pregnant patient, in a country where the drug had not been approved, from a manufacturer whose application was sitting unresolved at the FDA.
The Merrell connection remains central. The company that sought approval for the drug in 1960 is now a focus of the survivors' recognition effort in its home city of Cincinnati, where advocates have been pressing for acknowledgment and support. The geography is pointed: the same corporate history that features in the origin story of thalidomide in America is now involved in the effort to account for the Americans it touched.
The broader implication is a familiar one in regulatory history — the reforms that prevent future harm do not automatically repair the record of past harm. Kelsey's work spared the United States an approval-driven catastrophe and produced the review culture that now governs drug safety. It did not undo, or even necessarily document, the distribution of a drug that had already reached clinicians and patients outside the approval system.
That is why the survivors' demand for formal federal acknowledgment matters beyond the individuals involved. An official count would establish that the exposure happened domestically, that it was measurable, and that the population exists — the foundation on which medical recognition, historical record-keeping and any future response would rest. The measure of the gap is the quote that motivates Gwen Riechmann and others like her: a country that prevented a tragedy from being formally approved, but never fully counted its cost.
For the survivors, time is a factor. The adults who were born with thalidomide's signature deformities are aging, and the number of people who can still testify, document and press for that acknowledgment is shrinking. What they are asking for is not a new scientific debate, but a corrected one — a government willing to say, in its own records, that this happened here too.
(0)